Yes it's not new. It's on the shelf for years collecting dust.
But, things have since changed and is about to change in a much bigger way with marketing applications or application acceptance of DCVax-L about to break on any day, and particularly with increased awareness and unprecedented rich data re MOA, substantially improved OS, etc from DCVax-L trial for GBM.
So the general dynamic has changed. With that on mind, yesterday's "garbage" such as DCVax prostate P3 trial may be today's treasure.
I will not be surprised if that specific trial gets new interests with a partnership deal.
Bullish